| The Role of Lymphadenectomy in Endometrial Cancer was the ASTEC trial doomed by design and are we destined to repeat that mistake? | |
| | |
MedLine Citation:
|
PMID: 22555109 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: This study examines the design of previous and future trials of lymph node dissection in endometrial cancer. METHODS: Data from previous trials were used to construct a decision analysis modeling the risk of lymphatic spread and the effects of treatment on patients with endometrial cancer. This model was then applied to previous trials as well as other future trial designs that might be used to address this subject. RESULTS: Comparing the predicted and actual results in the ASTEC trial, the model closely mimics the survival results with and without lymph node dissection for the low and high risk groups. The model suggests a survival difference of less than 2% between the experimental and control arms of the ASTEC under all circumstances. Sensitivity analyses reveal that these conclusions are robust. Future trial designs were also modeled with hysterectomy only, hysterectomy with radiation in intermediate risk patients, and staging with radiation only with node positive patients. Predicted outcomes for these approaches yield survival rates of 88%, 90%, and 93% in clinical stage I patients who have a risk of pelvic node involvement of approximately 7%. These estimates were 78%, 82%, and 89% in intermediate risk patients who have a risk of nodal spread of approximately 15%. CONCLUSIONS: This model accurately predicts the outcome of previous trials and demonstrates that even if lymph node dissection was therapeutic, these trials would have been negative due to study design. Furthermore, future trial designs that are being considered would need to be conducted in high-intermediate risk patients to detect any difference. |
| | |
Authors:
|
R Wendel Naumann |
Related Documents
:
|
22626799 - Comparison of quality of life in patients undergoing transhiatal esophagectomy with or ... 22885469 - Lapatinib and potential prognostic value of egfr mutations in a gynecologic oncology gr... 22382509 - Validity of 6(th) edition of uicc tnm classification system for medullary thyroid carci... 22907659 - Aggressive multimodality management of locally advanced retromolar trigone tumors. 2403959 - Endometrioid stromal sarcomas arising from ovarian and extraovarian endometriosis: repo... 19282789 - Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-t... 3980269 - Radiotherapy for prostate carcinoma: the jcrt experience (1968-1978). ii. factors relat... 21703849 - Clinical outcome in children and adolescents with hodgkin lymphoma after treatment with... 16208029 - Breakthrough candida krusei fungemia during fluconazole prophylaxis followed by breakth... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-30 |
Journal Detail:
|
Title: Gynecologic oncology Volume: - ISSN: 1095-6859 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-5-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012. Published by Elsevier Inc. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: TRAIL-R3-Related Apoptosis: Epigenetic and Expression Analyses in Women with Ovarian Neoplasia.
Next Document: Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in pa...